U.S. District Court Upholds Validity of Lilly’s Alimta Patent Through 2022

INDIANAPOLIS, April 6, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
today announced that the U.S. District Court for the Southern District of
Indiana has ruled in the company’s favor regarding the vitamin dosage regimen
patent for Alimta® (pemetrexed for injection). In the case of Eli Lilly and
Company v. Teva Parenteral Medicines Inc., et al., the court ruled the vitamin
dosage regimen patent is valid and enforceable. The patent provides intellectual
property protection for Alimta until 2022. Alimta’s compound patent remains in
force through early 2017.

“We are pleased with the District Court’s ruling on Alimta’s vitamin dosage
regimen patent and are confident that the patent is valid and enforceable,” said
Michael J. Harrington, senior vice president and general counsel for Lilly. “The
significant scientific research that Lilly performed in support of the vitamin
dosage regimen patent deserves intellectual property protection. We continue to
emphasize that protection of intellectual property rights is extremely important
to the biopharmaceutical industry and the patients we serve. These rights
provide assurances of market exclusivity that help support the development of
the next generation of innovative medicines to treat unmet medical needs.”

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century ago
by a man committed to creating high-quality medicines that meet real needs, and
today we remain true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to those who need
them, improve the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more about Lilly,
please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

This release contains forward-looking statements regarding the U.S. Alimta
patent litigation. These statements are based on management’s current
expectations but actual results may differ materially. There can be no assurance
that the company will prevail in any appeal. Also, the company cannot predict
whether generic pemetrexed will be marketed prior to the resolution of this
litigation. Other risk factors that may affect the company’s results can be
found in the company’s latest Forms 10-K and 10-Q filed with the U.S. Securities
and Exchange Commission.

Alimta®(pemetrexed, Lilly)

Refer to: (317) 433-9899 (office); (317) 985-6303 (cell) – Edward Sagebiel


Logo- http://photos.prnewswire.com/prnh/20031219/LLYLOGO

SOURCE Eli Lilly and Company

Leave a Reply

Fatal error: Call to undefined function show_subscription_checkbox() in /home3/steer/public_html/indianapressreleases.com/wp-content/themes/comfy/comments.php on line 95